Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors

Inclusion Criteria

• •1. Pathologically proven diagnosis of a malignant salivary gland tumor of intermediate or high-grade
• •2. Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (≤ 5mm) or microscopically positive surgical margin
• •3. Surgical resection with curative intent within 8 weeks prior to registration, with no evidence of gross tumor residual
• •4. No evidence of distant metastases
• •5. No synchronous or concurrent head and neck primary tumors
• •6. Karnofsky score over 60
• •7. Adequate organ function including the following:
• •1. Absolute neutrophil count (ANC) \>= 1.5 \* 10\^9/l
• •2. Platelets count \>= 100 \* 10\^9/l
• •3. Hemoglobin \>= 10 g/dl
• •4. AST and ALT \<= 2.5 times institutional upper limit of normal (ULN)
• •5. Total bilirubin \<= 1.5 times institutional ULN
• •6. Creatinine clearance \>= 50 ml/min
• •7. Serum creatine \<= 1 times ULN
• •8. Signed written informed consent